Poor treatment compliance in children with down syndrome and acute lymphoblastic leukemia

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 1, 2009, Pages 79-80

  Bohnstedt, Catherine ^a   Taskinen, Mervi ^b   Zeller, Bernward ^c   Björgvinsdóttir, Helga ^d   Hafsteinsdottir, Solveig ^e   Schmiegelow, Kjeld ^a  

^a Rigshospitalet   (Denmark)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE; METHOTREXATE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CHILD; CLINICAL PROTOCOL; COMPLIANCE (PHYSICAL); CONTROLLED STUDY; DOWN SYNDROME; FEMALE; HUMAN; INFANT; LETTER; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PHYSICIAN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; STATISTICS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

6-MERCAPTOPURINE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; FEMALE; GUIDELINE ADHERENCE; HUMANS; INFANT; MALE; METHOTREXATE; NEOPLASM RECURRENCE, LOCAL; PATIENT COMPLIANCE; PHYSICIAN'S ROLE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 59449083763     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31818b37a9     Document Type: Letter

References (17)

1. Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol. 2001;2:429-436.
2. Zeller B, Gustafsson G, Forestier E, et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol. 2005;128:797-804.
3. Chessells JM, Harrison G, Richards SM, et al. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child. 2001;85:321-325.
4. Whitlock JA, Sather HN, Gaynon P, et al. Clinical characteristics and outcome of children with down syndrome and acute lymphoblastic leukemia: a children's cancer group study. Blood. 2005;106: 4043-4049.
5. Dordelmann M, Schrappe M, Reiter A, et al. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group [see comments]. Leukemia. 1998; 12:645-651.
6. Kalwinsky DK, Raimondi SC, Bunin NJ, et al. Clinical and biological characteristics of acute lymphocytic leukemia in children with Down syndrome. Am J Med Genet Suppl. 1990;7:267-271.
7. Ragab AH, bdel-Mageed A, Shuster JJ, et al. Clinical characteristics and treatment outcome of children with acute lymphocytic leukemia and Down's syndrome. A Pediatric Oncology Group study. Cancer. 1991;67:1057-1063.
8. Bassal M, La MK, Whitlock JA, et al. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer. 2005;44:21-28.
9. Forestier E, Izraeli S, Beverloo B, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood. 2008;111: 1575-1583.
10. Karrman K, Forestier E, Andersen MK, et al. High incidence of the ETV6/RUNX1 fusion gene in paediatric precursor B-cell acute lymphoblastic leukaemias with trisomy 21 as the sole cytogenetic change: a Nordic series of cases diagnosed 1989-2005. Br J Haematol. 2006;135: 352-354.
11. Taub JW, Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer. 2005;44:33-39.
12. Taub JW, Huang X, Matherly LH, et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood. 1999;94:1393-1400.
13. Taub JW, Matherly LH, Stout ML, et al. Enhanced metabolism of 1-beta-D-arabi-nofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood. 1996;87:3395-3403.
14. Schmiegelow K, Bjork O, Glomstein A, et al. Intensification of mercaptopurine/ methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol. 2003;21:1332-1339.
15. Schmiegelow K, Glomstein A, Kristinsson J, et al. Impact of morning versus evening schedule for oral methotrexate and 6-mer-captopurine on relapse risk for children with acute lymphoblastic leukaemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO). J Pediatr Hematol Oncol. 1997;19:102-109.
16. Lancaster D, Lennard L, Lilleyman JS. Profile of non-compliance in lymphoblastic leukaemia. Arch Dis Child. 1997;76:365-366.
17. Olesen KM, Honore S, Sidenius U, et al. Determination of DNA 6-thioguanine nucleotide levels by high-performance liquid chromatography with fluorescence detection. J Chromatogr B. 2008;864: 149-155.